Skip to content
AnalystLens

Moderna, Inc. 8-K Report, Executive Changes (Mar 30, 2020)

Reports
Leadership Changes·Other Events·Exhibits & Filings
Filing Date
Filed March 30, 2020
Period End
March 29, 2020
Security
MRNA
In the record · 2018–202610-K910-Q238-K117

MRNA filed 9 annual reports (10-K), 23 quarterly reports (10-Q) and 117 current reports (8-K) between 2018 and 2026.

  1. Material agreement8-K · May ’19May ’19
  2. Leadership change8-K · Sep ’22Sep ’22
  3. Leadership change8-K · Sep ’26Sep ’26

01—Abstract

Summary

Summary of the 8-K filed March 30, 2020. Cited figures are marked; the original filing is the authoritative source.

Moderna, Inc. (MRNA) filed an 8-K on March 30, 2020, reporting on the business and clinical program impact of COVID-19, and a key executive retention agreement.

The company issued a press release on March 29, 2020, providing an update on how the COVID-19 pandemic was affecting its operations and development pipeline. While specific details on the impact are within the referenced press release (Exhibit 99.1), this filing signals management's active communication regarding the pandemic's influence. In addition to operational updates, the filing details an Executive Retention Agreement with Chief Medical Officer (CMO) Tal Zaks, M.D.

The agreement secures Dr. Zaks' continued service through at least September 30, 2021, and includes a $1,000,000a retention bonus if he remains employed through that date or if his employment is terminated by the company without cause prior to that date. This retention effort highlights the importance of key leadership in navigating the company's critical development programs, especially during the evolving COVID-19 landscape.

02—Key points

Key Highlights

  1. Moderna announced an update on the impact of COVID-19 on its business operations and clinical development programs via a March 29, 2020 press release.
  2. An Executive Retention Agreement was signed with Chief Medical Officer (CMO) Tal Zaks, M.D.
  3. Dr. Zaks' agreement ensures his continued service as CMO through at least September 30, 2021.
  4. A $1,000,000 retention bonus is stipulated for Dr. Zaks, payable under specific employment continuation or termination conditions.
  5. The agreement specifies terms for the exercisability of Dr. Zaks' stock options upon termination of employment.
  6. This filing indicates proactive management communication regarding pandemic impacts and efforts to retain key personnel during a critical period.

03—Questions

Frequently Asked Questions

  1. What is the primary purpose of this 8-K filing?

    The primary purpose of this 8-K filing is to announce updates regarding the impact of the COVID-19 pandemic on Moderna's business and clinical programs, and to disclose an executive retention agreement with its Chief Medical Officer.

  2. What is the significance of the Executive Retention Agreement with Dr. Tal Zaks?

    The agreement secures the continued service of Dr. Zaks, the CMO, through at least September 30, 2021. This is significant as it demonstrates Moderna's commitment to retaining key leadership talent, especially during the critical development phases of its product pipeline and amidst the uncertainties of the COVID-19 pandemic. It also includes financial incentives for his retention.

  3. Where can I find more details about the impact of COVID-19 on Moderna's business?

    More specific details regarding the impact of COVID-19 on Moderna's business operations and clinical program development can be found in the press release issued by the company on March 29, 2020, which is attached as Exhibit 99.1 to this 8-K filing.

  4. What are the conditions for Dr. Zaks receiving the $1,000,000 retention bonus?

    Dr. Zaks will receive the $1,000,000 retention bonus provided he remains continuously employed by Moderna through September 30, 2021, or if his employment is terminated by the company without 'Cause' (as defined in the Severance Plan) prior to that date.

04—Continue

← View all 8-K filings